Harmless Clostridium bacteria as a highly targeted, continuous delivery system for immunomodulatory anti-cancer drugs

Resultado final

D1.1 Report on training program oncology (M12)

D1.2 Report on training program business aspects (M12)

Publicaciones

Spores of <i>Clostridium</i> engineered for clinical efficacy and safety cause regression and cure of tumors <i>in vivo</i>

Autores: John T. Heap, Jan Theys, Muhammad Ehsaan, Aleksandra M Kubiak, Ludwig Dubois, Kim Paesmans, Lieve Van Mellaert, Richard Knox, Sarah A. Kuehne, Phillipe Lambin, Nigel P. Minton
Publicado en: Oncotarget, Edición 5/7, 2014, ISSN 1949-2553
Editor: Impact Journals
DOI: 10.18632/oncotarget.1761

The potential of clostridial spores as therapeutic delivery vehicles in tumour therapy

Autores: Aleksandra M. Kubiak, Nigel P. Minton
Publicado en: Research in Microbiology, Edición 166/4, 2015, Página(s) 244-254, ISSN 0923-2508
Editor: Elsevier BV
DOI: 10.1016/j.resmic.2014.12.006

Advancing Clostridia to Clinical Trial: Past Lessons and Recent Progress

Autores: Alexandra Mowday, Christopher Guise, David Ackerley, Nigel Minton, Philippe Lambin, Ludwig Dubois, Jan Theys, Jeff Smaill, Adam Patterson
Publicado en: Cancers, Edición 8/7, 2016, Página(s) 63, ISSN 2072-6694
Editor: Multidisciplinary Digital Publishing Institute (MDPI)
DOI: 10.3390/cancers8070063

Resultado final

Publicaciones

Compartir esta página

Descargar